Cytokinetics INC Form 4 insider transactions

Director Robert Arthur Harrington of Cytokinetics Inc. (CYTK) sold 253 shares of common stock at a price of $54.61 on July 5, 2024.

Director Nancy Wysenski acquired 114 shares of Cytokinetics Inc. common stock on July 1, 2024, in lieu of a cash retainer payment.

Director Wendell Wierenga acquired 114 shares of Cytokinetics Inc. common stock on July 1, 2024, as a stock award in lieu of a cash retainer payment.

Director Edward M. Kaye acquired 228 shares of Cytokinetics Inc. common stock on July 1, 2024, as a stock award in lieu of a cash retainer payment.

Director John T. Henderson reports acquiring 388 shares of Cytokinetics Inc. common stock in lieu of a cash retainer payment.

Director Robert Arthur Harrington acquired 228 shares of Cytokinetics Inc. common stock on July 1, 2024, as a stock award in lieu of a cash retainer payment.

Director Lynne Parshall exercised stock options and sold shares of Cytokinetics Inc. on July 1, 2024.

Cytokinetics CEO Robert Blum sold 11,500 shares of common stock at $54.05 per share on July 1, 2024, according to a Form 4 filing.

Fady Ibraham Malik, EVP of Research & Development at Cytokinetics, reported the acquisition and disposal of company stock on June 25, 2024.

Director Lynne Parshall exercised stock options and sold shares of Cytokinetics on June 17, 2024.

Cytokinetics CEO Robert Blum sold a portion of his common stock holdings on June 17, 2024.

Fady Ibraham Malik, EVP of Research & Development at Cytokinetics, reports the exercise of stock options and subsequent sale of shares on June 11, 2024.

Director Muna Bhanji sold 2,000 shares of Cytokinetics Inc. (CYTK) at a price of $52.07 on June 10, 2024.

Cytokinetics' CEO, Robert I. Blum, sold 22,500 shares of common stock at $48.85 per share on June 4, 2024, under a pre-arranged 10b5-1 trading plan.

Robert Arthur Harrington, a director at Cytokinetics Inc, sold 1,580 shares of common stock at a price of $48.64 per share on June 3, 2024.

Director Lynne Parshall exercised stock options and sold shares of Cytokinetics Inc. on June 3, 2024.

EVP and CFO of Cytokinetics, Sung Lee, reports acquisition of restricted stock units and non-qualified stock options.

Robert Wong, VP, Chief Accounting Officer of Cytokinetics Inc, sold 13,011 shares of common stock on June 3, 2024, at a price of $48.88 per share.

Director Muna Bhanji reports acquisition and disposal of Cytokinetics Inc. common stock and acquisition of non-qualified stock options.

Director Santo J. Costa reports acquisition and disposal of Cytokinetics Inc. common stock and acquisition of non-qualified stock options.

Director Robert Arthur Harrington reports acquisition of Cytokinetics shares and stock options on May 15, 2024.

Director John T. Henderson reports acquisition and disposal of Cytokinetics Inc. common stock and acquisition of non-qualified stock options.

Director Edward M. Kaye reported acquiring 5,600 shares of Cytokinetics common stock and disposing of 24,917 shares, along with acquiring options to purchase 3,636 shares.

Director Lynne Parshall reported the acquisition and disposal of Cytokinetics Inc. common stock and stock options on May 15, 2024.

Wendell Wierenga, a director at Cytokinetics Inc, reported acquiring 5,600 shares of common stock and 3,636 non-qualified stock options on May 15, 2024.

Director Nancy Wysenski reports acquisition of Cytokinetics stock and stock options.

Fady Ibraham Malik, EVP of Research & Development at Cytokinetics, exercised stock options and sold shares of common stock under a pre-arranged 10b5-1 trading plan.

Director John T. Henderson sold 10,562 shares of Cytokinetics Inc. common stock at $64.54 per share on April 25, 2024, under a pre-arranged 10b5-1 trading plan.

Fady Ibraham Malik, EVP of Research & Development at Cytokinetics, reported a gift of 150 shares of common stock on April 12, 2024.

Fady Ibraham Malik, EVP of Research & Development at Cytokinetics, exercised stock options and sold shares on April 9, 2024.